Says Slone Partners CEO Leslie Loveless, “Coupling Dr. Czerwiec’s remarkable kidney-focused experience with Goldfinch now creates brighter possibilities for new targeted drugs which could truly make a difference for a large and underserved patient population.”
Boston, MA (PRWEB) January 08, 2019
Slone Partners, North America’s leading executive search firm for life sciences and diagnostics companies, announces the placement of Frank Czerwiec as Chief Medical Officer at Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases. In this newly created role, he is responsible for leading all aspects of clinical strategy and clinical development, including biostatistics, pharmacokinetics, pharmacometrics, clinical operations, medical affairs and pharmacovigilance/drug safety. Dr. Czerwiec is now based at Goldfinch Bio’s headquarters in Cambridge, Massachusetts and reports to Anthony Johnson, M.D., President and Chief Executive Officer.
Dr. Czerwiec joins Goldfinch Bio from Otsuka Pharmaceutical Development & Commercialization, Inc. where he was most recently Vice President, Global Clinical Development, leading their Cardio-Renal and Metabolic/Medicine group. During his 20-year tenure at Otsuka he was a key contributor to multiple drug approvals and led the global Tolvaptan program in autosomal dominant polycystic kidney disease (ADPKD). During his career Dr. Czerwiec has been an active supporter of kidney disease-related research including the Critical-Path’s PKD Outcomes Consortium, Kidney Drug Development Tools Summit and ADPKD Summit. He has contributed to the National Kidney Foundation's Patient Reported Outcome Initiative and ASN’s Kidney Health Initiative. Dr. Czerwiec earned his M.D. and a Ph.D. in Biochemistry and Molecular Biology and conducted his internal medicine residency at the University of Miami Miller School of Medicine before completing his post-doctoral training in translational research through a fellowship in Adult Endocrinology and Metabolism at the National Institutes of Health (NIH) (NICHD & NIDDK).
"Working with Slone Partners was a pleasure. Their approach was entirely professional and respectful of all parties involved, and they thoughtfully addressed my concerns and questions. Having been with my previous company for over 20 years, Slone Partners helped make the transition to Goldfinch Bio not only feasible, but exciting,” says Frank Czerwiec M.D., Ph.D.
Says Slone Partners CEO Leslie Loveless, “Goldfinch Bio is the leading life sciences and precision medicine company working passionately on kidney diseases which now affect over 800 million people worldwide. Coupling Dr. Czerwiec’s remarkable kidney-focused experience with Goldfinch now creates brighter possibilities for new targeted drugs which could truly make a difference for a large and underserved patient population.”
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing scientific healthcare organizations - People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, diagnostics, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to innovative scientific healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit slonepartners.com or call 888.784.3422.
ABOUT GOLDFINCH BIO
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney diseases. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, MA. For more information, please visit http://www.goldfinchbio.com.